by Collectif | 13 Jan, 2017 | Bioethics press synthesis
Johann Roduit[1], from the Centre for Medical Humanities at Zurich University, announced in a forum that we are witnessing “an individualisation of responsibilities and a decrease in solidarity between individuals”. He went on, that unfortunately,...
by Collectif | 13 Jan, 2017 | Bioethics press synthesis | Abortion - Medical termination of Pregnancy(MTP)
In the US State of Ohio, the Senate approved a draft bill banning abortion after the detection of a foetal heart beat, usually around six weeks after conception. The draft bill was sent to the Chamber for approval. Eventually, Ohio Governor, John Kasich,...
by Collectif | 13 Jan, 2017 | Bioethics press synthesis | Abortion - Medical termination of Pregnancy(MTP)
The 5th annual meeting of the Ouagadougou Partnership took place in Abidjan on 14 December. The aim of this partnership is to “accelerate the use of Family Planning” services in 9 French-speaking African countries. This meeting focuses on “promoting...
by Collectif | 13 Jan, 2017 | Bioethics press synthesis | Abortion - Medical termination of Pregnancy(MTP)
Gian Luigi Gigli[1] comments in court on the consequences of proposing offence to obstruct abortion legislation. According to the MP, the introduction of this draft bill into an Italian scenario “sheds light on the extent of this freedom-destroying law, which...
by Collectif | 13 Jan, 2017 | Bioethics press synthesis | Embryo research and alternatives
To develop its “bio-artificial pancreas” for the treatment of insulin-dependent diabetes, the Defymed Company has formed a partnership with the American Company, Semma, for the supply of stem cells. The cells provided by the Company are...
by Collectif | 13 Jan, 2017 | Bioethics press synthesis | Embryo research and alternatives
The Bayer and Versant Ventures Companies have created a cell therapy firm called Therapeutics BlueRock in an attempt to develop iPS-based cell therapies [1] for cardiovascular diseases and neurodegenerative disorders. Based in New York and Boston, the Company will...
